The two startups will utilise the capital for business growth including strategic expansion, product development, R&D and technology investments
The addition of Abexxa’s expertise complements Boehringer Ingelheim’s current approaches to the treatment of difficult-to-treat solid cancers and especially those resistant to available immunotherapies
Industry leaders to increase patient access to clinical research and scale remote enrollment of participants for trial sponsors to promote increased health equity
Ampion is directly administered by inhalation and it allows the drug to directly target and attenuate inflammation in the lungs
These aprons utilise phase change materials that absorb, store and release heat for optimal thermal comfort
In participants 5 to 11 years of age, the vaccine was safe, well-tolerated and showed robust neutralising antibody responses. Results in children under 5 years of age are expected as soon as later this year
MeMed BV is a first-of-its-kind test that decodes the immune response to accurately distinguish between bacterial or viral infections within minutes
The approval will enable the treatment of patients in India living with Essential tremor, tremor-dominant Parkinson's Disease and neuropathic pain
Over 61 per cent of pharmacists stated that they aim to improve their knowledge and medical skills while 76 per cent collaborated with healthcare players to improve the outcome for their patients
BB will have access to 100 million doses of vaccines annually and commercialization rights of the SILS vaccine portfolio for global markets
Subscribe To Our Newsletter & Stay Updated
